Merrimack''s partner Ipsen had a recent failure of the applications of its drug ONIVYDE. Read more to find out what this means for MACK stock.
→ Google 번역
Merrimack Pharmaceuticals press release (MACK): Q2 GAAP EPS of -$0.04.As of June 30, 2022, Merrimack had cash and cash equivalents of $13.4 million, compared to $14.2 million as…
→ Google 번역
Merrimack Pharmaceuticals Inc''s (NASDAQ: MACK ) partner announced that Ipsen SA (OTC: IPSEY ) reported a primary analysis of the results of the Phase 3 trial of Onivyde (irinotecan liposomal injection)for second-line small cell lung cancer (SCLC). The study did not meet the primary endpoint of overall survival in patients treated with Onivyde … Full story available on Benzinga.com
→ Google 번역
(RTTNews) - Merrimack Pharmaceuticals, Inc. (MACK) said Ipsen has reported its primary analysis of the results of phase 3 trial of Onivyde as a treatment of second line small cell lung cancer. The primary endpoint OS was not met in patients treated with Onivyde versus topotecan.
→ Google 번역
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 3, 2022-- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) [(“Merrimack” or the “Company”)] announced that Ipsen, SA (“Ipsen”) has issued a press release today reporting its primary analysis of the results of its Phase 3 trial of Onivyde® (irinotecan liposomal
→ Google 번역
Merrimack Pharmaceuticals press release (MACK): Q1 GAAP EPS of -$0.01.“During the first quarter of 2022 we continued to see reductions in our operating expenses and were able to close…
→ Google 번역
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 5, 2022-- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) [(“Merrimack” or the “Company”)] today announced its first quarter 2022 financial results for the period ended March 31, 2022 . “During the first quarter of 2022 we continued to see reductions in our
→ Google 번역
Merrimack Pharmaceuticals press release (MACK): FY GAAP EPS of -$0.18.As of December 31, 2021, Merrimack had cash and cash equivalents and investments of $14.2 million, compared to…
→ Google 번역
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 12) 4D Molecular Therapeutics Inc (NASDAQ: FDMT ) Adagene Inc (NASDAQ: ADAG ) (went public Tuesday) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) AnaptysBio Inc (NASDAQ: ANAB ) (received a double upgrade from JPMorgan) AngioDynamics, Inc. (NASDAQ: ANGO ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) argenx SE – ADR (NASDAQ: ARGX ) Atea Pharmaceuticals Inc (NASDAQ: AVIR ) AtriCure Inc. (NASDAQ: ATRC ) Ayala Pharmaceuticals Inc (NASDAQ: AYLA ) Bausch Health Companies Inc (NYSE: BHC ) Bolt Biotherapeutics Inc (NASDAQ: BOLT ) C4 Therapeutics Inc (NASDAQ: CCCC ) Cara Therapeutics Inc (NASDAQ: CARA ) Celcuity Inc (NASDAQ: CELC ) Checkpoint Therapeutics Inc (NASDAQ: CKPT ) Collplant Biotechnologies Ltd – ADR (NASDAQ: CLGN ) DermTech Inc (NASDAQ: DMTK ) ( announced award of contract for coverage of its skin cancer gene expression test) ESSA Pharma Inc (NASDAQ: EPIX ) (reacted to first-quarter results) Evogene Ltd (NASDAQ: EVGN ) FibroGen Inc (NASDAQ: FGEN ) G1 Therapeutics Inc (NASDAQ: GTHX ) Genetron Holdings Ltd – ADR (NASDAQ: GTH ) GenMark Diagnostics, Inc (NASDAQ: GNMK ) (moved on M&A speculation) Guardant Health Inc (NASDAQ: GH ) Guardion Health Sciences Inc (NASDAQ: GHSI ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunome Inc (NASDAQ: IMNM ) Infinity Pharmaceuticals Inc.
→ Google 번역
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 11) 10X Genomics Inc (NASDAQ: TXG ) 9 Meters Biopharma Inc (NASDAQ: NMTR ) Abbott Laboratories (NYSE: ABT ) Acasti Pharma Inc (NASDAQ: ACST ) (reacted to its quarterly results) Advaxis, Inc. (NASDAQ: ADXS ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Alimera Sciences Inc (NASDAQ: ALIM ) Alkermes Plc (NASDAQ: ALKS ) Allakos Inc (NASDAQ: ALLK ) Anchiano Therapeutics Ltd – ADR (NASDAQ: ANCN AngioDynamics, Inc. (NASDAQ: ANGO ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) Apyx Medical Corp (NASDAQ: APYX ) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR ) Artelo Biosciences Inc (NASDAQ: ARTL ) Aslan Pharmaceuticals Ltd (NASDAQ: ASLN ) AtriCure Inc. (NASDAQ: ATRC ) Avanos Medical Inc (NYSE: AVNS ) Beigene Ltd (NASDAQ: BGNE ) Bio-Path Holdings Inc (NASDAQ: BPTH ) (announced receipt of third patent related to manufacture of platform technology) Bolt Biotherapeutics Inc (NASDAQ: BOLT ) C4 Therapeutics Inc (NASDAQ: CCCC ) Cancer Genetics Inc (NASDAQ: CGIX ) (reacted to an update to merger terms with StemoniX) Cara Therapeutics Inc (NASDAQ: CARA ) Celcuity Inc (NASDAQ: CELC ) Cellular Biomedicine Group Inc (NASDAQ: CBMG ) Clearpoint Neuro Inc (NASDAQ: CLPT ) Clearside Biomedical Inc (NASDAQ: CLSD ) Collegium Pharmaceutical Inc (NASDAQ: COLL ) Collplant Biotechnologies Ltd – ADR (NASDAQ: CLGN ) Edap Tms SA (NASDAQ: EDAP ) Evogene Ltd (NASDAQ: EVGN ) Eyenovia Inc (NASDAQ: EYEN ) G1 Therapeutics Inc (NASDAQ: GTHX ) Gamida Cell Ltd (NASDAQ: GMDA ) ( reacted to a positive late-stags readout) Genetron Holdings Ltd – ADR (NASDAQ: GTH ) Glaukos Corp (NYSE: GKOS ) Guardion Health Sciences Inc (NASDAQ: GHSI ) Ideaya Biosciences Inc (NASDAQ: IDYA ) Illumina, Inc.
→ Google 번역
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 2) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) Beam Therapeutics Inc (NASDAQ: BEAM ) Bioanalytical Systems, Inc. (NASDAQ: BASI ) Cerevel Therapeutics Holdings Inc (NASDAQ: CERE ) Fate Therapeutics Inc (NASDAQ: FATE ) Generation Bio Co (NASDAQ: GBIO ) Idera Pharmaceuticals Inc (NASDAQ: IDRA ) Infinity Pharmaceuticals Inc. (NASDAQ: INFI ) Inhibrx Inc (NASDAQ: INBX ) Intellia Therapeutics Inc (NASDAQ: NTLA ) Iovance Biotherapeutics Inc (NASDAQ: IOVA ) Inspire Medical Systems Inc (NYSE: INSP ) Kymera Therapeutics Inc (NASDAQ: KYMR ) Larimar Therapeutics Inc (NASDAQ: LRMR ) Merrimack Pharmaceuticals Inc (NASDAQ: MACK ) (reacted to positive outlook for the cancer drug it sold to Ispen, which opens the possibility of realizing potential milestone payments) Myovant Sciences Ltd (NYSE: MYOV ) Ocular Therapeutix Inc (NASDAQ: OCUL ) Olema Pharmaceuticals Inc (NASDAQ: OLMA ) Oncorus Inc (NASDAQ: ONCR ) OncoSec Medical Inc (NASDAQ: ONCS ) Pfizer Inc. (NYSE: PFE ) ( announced U.K. regulatory nod for emergency use of its coronavirus vaccine candidate) Praxis Precision Medicines Inc (NASDAQ: PRAX ) Pulse Biosciences Inc (NASDAQ: PLSE ) Spero Therapeutics Inc (NASDAQ: SPRO ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Dec. 2) Histogen Inc (NASDAQ: HSTO ) Nabriva Therapeutics PLC – ADR (NASDAQ: NBRV ) (shares will trade …
→ Google 번역
Gainers Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK ) shares climbed … Full story available on Benzinga.com
→ Google 번역
Merrimack Pharmaceuticals (NASDAQ: MACK ) shares were trading higher on Wednesday in response to a corporate medical presentation given by Ipsen S.A. on Tuesday. Seeking Alpha said in the R&D section, management presented relevant updates (slide 42) on Onivyde (irinotecan … Full story available on Benzinga.com
→ Google 번역
Gainers Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) shares jumped 42.7% to $5.82. Merrimack Pharmaceuticals, last month, reported a loss for the third …
→ Google 번역
The 1st U.S. Circuit Court of Appeals on Friday upheld the convictions and prison sentences of former Akebia Therapeutics Inc and Merrimack Pharmaceuticals Inc employees who were found to have taken part in an insider trading scheme.
→ Google 번역
Merrimack Pharmaceuticals, Inc. today announced its third quarter 2020 financial results for the period ended September 30, 2020. “We are pleased that both Ipsen Pharmaceuticals and… | November 5, 2020
→ Google 번역
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals Q3 2020 Earnings Release
→ Google 번역
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 19.) Biomerica, Inc. (NASDAQ: BMRA ) Centogene NV (NASDAQ: CNTG ) Gilead Sciences, Inc. (NASDAQ: GILD ) Imara Inc (NASDAQ: IMRA ) Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) Down In The Dumps (Biotech stocks that hit 52-week lows March 19.) Acasti Pharma Inc (NASDAQ: ACST ) Accelerate Diagnostics Inc (NASDAQ: AXDX ) Acer Therapeutics Inc (NASDAQ: ACER ) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO ) Aikido Pharma Inc (NASDAQ: AIKI ) Alpine Immune Sciences Inc (NASDAQ: ALPN ) Amphastar Pharmaceuticals Inc (NASDAQ: AMPH ) Anika Therapeutics Inc (NASDAQ: ANIK ) Anixa Biosciences Inc (NASDAQ: ANIX ) AnPac Bio-Medical Science Co Ltd – ADR (NASDAQ: ANPC ) Antares Pharma Inc (NASDAQ: ATRS ) Apyx Medical Corp (NASDAQ: APYX ) Arca Biopharma Inc (NASDAQ: ABIO ) Aridis Pharmaceuticals Inc (NASDAQ: ARDS ) aTyr Pharma Inc (NASDAQ: LIFE ) AVEO Pharmaceuticals, Inc.
→ Google 번역
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Feb. 26.) Co-Diagnostics Inc (NASDAQ: CODX ) Fate Therapeutics Inc (NASDAQ: FATE ) Gilead Sciences, Inc. (NASDAQ: GILD ) Inspire Medical Systems Inc (NYSE: INSP ) (reacted to fourth-quarter results) Mersana Therapeutics Inc (NASDAQ: MRSN ) Moderna Inc (NASDAQ: MRNA ) Nevro Corp (NYSE: NVRO ) (announced fourth-quarter results) Oyster Point Pharma Inc (NASDAQ: OYST ) Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) Revolution Medicines Inc (NASDAQ: RVMD ) Vir Biotechnology Inc (NASDAQ: VIR ) (announced a collaboration with WuXi Biologics for the development of antibodies to treat COVID-19) Down In The Dumps (Biotech stocks that hit 52-week lows Feb. 26.) ABIOMED, Inc. (NASDAQ: ABMD ) Accelerate Diagnostics Inc (NASDAQ: AXDX ) AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) Acorda Therapeutics Inc (NASDAQ: ACOR ) AngioDynamics, Inc. (NASDAQ: ANGO ) ANCHIANO THERAP/S ADR (NASDAQ: ANCN ) Aptevo Therapeutics Inc (NASDAQ: APVO ) Auris Medical Holding Ltd (NASDAQ: EARS )(announced publication of results of a study showing anti-epileptic and anti-convulsive activity of betahistine in a mouse model) Blueprint Medicines Corp (NASDAQ: BPMC ) Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX ) Curis, Inc. (NASDAQ: CRIS ) Enochian Biosciences Inc (NASDAQ: ENOB ) Galectin Therapeutics Inc.
→ Google 번역
Mubasher: US-based Merrimack Pharmaceuticals has received $5 million milestone payment from French pharmaceutical company Ipsen.
→ Google 번역
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals, Inc. adopts section 382 net operating loss rights plan.
→ Google 번역
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Nov. 21.) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Amgen, Inc. (NASDAQ: AMGN ) (raised full-year guidance following completion of Otezla purchase from Celgene) Antares Pharma Inc (NASDAQ: ATRS ) Arvinas Inc (NASDAQ: ARVN ) Axsome Therapeutics Inc (NASDAQ: AXSM ) Beigene Ltd (NASDAQ: BGNE ) BIO-TECHNE Corp (NASDAQ: TECH ) BridgeBio Pharma Inc (NASDAQ: BBIO ) Cue Biopharma Inc (NASDAQ: CUE ) Epizyme Inc (NASDAQ: EPZM ) Kamada Ltd. (NASDAQ: KMDA ) Kodiak Sciences Inc (NASDAQ: KOD ) Molecular Templates Inc (NASDAQ: MTEM ) Recro Pharma Inc (NASDAQ: REPH ) (completed spin-off of Baudax Bio in a bid to a become a pure play CDMO) Down In The Dumps (Biotech stocks that hit 52-week lows on Nov. 21.) AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) (received European approval for its Rhokiinsa 0.02% for the reduction of elevated intraocular pressure) Affimed NV (NASDAQ: AFMD ) Anixa Biosciences Inc (NASDAQ: ANIX ) CareDx Inc (NASDAQ: CDNA ) Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX ) ENDRA Life Sciences Inc (NASDAQ: NDRA ) Genprex Inc (NASDAQ: GNPX ) Idera Pharmaceuticals Inc (NASDAQ: IDRA ) Interpace Biosciences Inc (NASDAQ: IDXG ) Invivo Therapeutics Holdings Corp (NASDAQ: NVIV ) (priced its previously announced common stock offering) Iterum Therapeutics PLC (NASDAQ: ITRM ) Jaguar Health Inc (NASDAQ: JAGX ) MacroGenics Inc (NASDAQ: MGNX ) Merrimack Pharmaceuticals Inc (NASDAQ: MACK ) Neon Therapeutics Inc (NASDAQ: NTGN ) (announced a changed focus and the elimination of 24% of workforce) Novavax, Inc. (NASDAQ: NVAX ) Nuvectra Corp (NASDAQ: NVTR ) Onconova Therapeutics …
→ Google 번역